selank mastery course
Unit 9 of 11
dosing and administration
intranasal protocols, community practices, and stacking with semax
dosing and administration
this unit documents community-reported selank dosing protocols, intranasal spray preparation, stacking with semax, and cycling patterns. the content below reflects what the community uses, not prescriptive medical advice. product quality from unregulated sources varies and is a significant risk factor.
this unit documents community-reported dosing practices for educational purposes only. this is not medical advice. product quality from unregulated sources varies significantly and is a major risk factor.
dosing at a glance
key parameters from clinical protocols and community practices.
200-300 mcg
clinical dose per administration (intranasal)
intranasal
primary route -- nasal spray or drops
14 days
standard clinical treatment cycle duration
0.1%
typical concentration of commercial Russian formulation
interactive explorer
explore the key concepts for this unit.
dosing and administration guide
key terms
definitions you will encounter throughout this unit.
I
administering a drug through the nasal cavity via spray or drops. the nasal mucosa (lining) is highly vascularized (rich in blood vessels) and provides rapid absorption. for peptides like selank, intranasal delivery also offers a potential direct-to-brain pathway via olfactory nerve endings in the upper nasal cavity.
R
the process of dissolving a freeze-dried (lyophilized) peptide powder in a sterile liquid to create a usable solution. community users typically reconstitute selank with bacteriostatic water (sterile water containing 0.9% benzyl alcohol as a preservative) and transfer to a nasal spray bottle.
B
sterile water containing 0.9% benzyl alcohol, which inhibits bacterial growth. used for reconstituting peptides because it extends the usable life of the solution compared to plain sterile water. the benzyl alcohol preservative prevents contamination during repeated use.
S
the practice of using selank and semax (another Russian regulatory peptide derived from ACTH) together. community users report complementary effects: selank for anxiety reduction and semax for cognitive enhancement and motivation. both are administered intranasally. no formal clinical study has evaluated this combination.
C
alternating periods of using and not using a substance. in the peptide community, cycling typically means using selank for a set period (e.g., 14-30 days) then taking a break. the rationale is to prevent potential tolerance, though no tolerance to selank has been documented in clinical studies.
H
a pragmatic approach that aims to minimize risks associated with substance use without requiring abstinence. in the context of research peptides, harm reduction includes: sourcing from reputable suppliers, using sterile preparation techniques, starting with lower doses, and monitoring for adverse effects.
administration routes
how selank is delivered in clinical and community settings.
intranasal spray
clinical standard -- the only route used in approved Russian formulations. 0.1% solution delivered via metered nasal spray. rapid onset (minutes). commercially available in Russia as a pharmacy product.
nasal drops
community alternative -- reconstituted peptide transferred to a dropper bottle. less precise dosing than metered spray. commonly used by community members who reconstitute lyophilized powder.
subcutaneous
community off-label -- some users inject subcutaneously. not used in any clinical trial or approved formulation. PK profile for this route is not characterized. carries additional contamination and injection-site risks.
how intranasal delivery works -- the simple version
why spraying a peptide into your nose can get it into your brain.
most drugs you swallow get destroyed by stomach acid and liver enzymes before they reach the bloodstream -- this is called first-pass metabolism (the liver's filtering of everything absorbed from the gut). peptides like selank are especially vulnerable because digestive enzymes are specifically designed to break down peptide bonds. intranasal delivery (spraying the drug into the nose) solves this by bypassing the digestive system entirely. the nasal cavity is lined with a thin, blood-vessel-rich membrane called the nasal mucosa. small molecules can pass through this membrane directly into the bloodstream. but for peptides targeting the brain, there is an even more direct route: the olfactory nerve pathway. nerve endings in the upper nasal cavity connect directly to brain tissue, allowing some molecules to travel along these nerves into the brain without ever entering the general blood circulation or crossing the blood-brain barrier (the tightly packed cell layer that blocks most molecules from entering the brain from the blood).
A
the olfactory epithelium (the smell-sensing tissue in the upper nasal cavity) contains nerve cells that project directly into the olfactory bulb, a brain structure sitting just above the nasal cavity separated only by the thin cribriform plate (a perforated bone). molecules deposited on the olfactory epithelium can travel along the outside of these nerve fibers through the perineural space (the channels surrounding nerve bundles) and reach the brain within minutes. from the olfactory bulb, they can distribute to the hippocampus, amygdala, and cortex -- all regions involved in anxiety processing. radiolabeled studies in rodents (experiments using radioactive tags to track molecule movement) confirmed that intranasally administered selank reaches these brain regions at concentrations higher than would be expected from blood circulation alone, supporting the nose-to-brain transport theory.
advanced: reconstitution and storage
selank is typically supplied as a lyophilized powder (freeze-dried to remove water, which preserves the peptide's structure during storage). before use, it must be reconstituted (dissolved) in a sterile liquid -- usually bacteriostatic water (sterile water containing 0.9% benzyl alcohol as a preservative). the reconstitution process requires gentle swirling, not vigorous shaking, because aggressive agitation can denature (unfold and damage) the peptide. once reconstituted, the solution should be stored refrigerated at 2-8 degrees celsius and used within a few weeks. the lyophilized powder itself is more stable and can be stored frozen for months. temperature excursions (leaving the solution at room temperature for extended periods) accelerate degradation and reduce potency. this cold-chain requirement is one reason why peptide therapeutics are more logistically complex than conventional pills.
advanced: bioavailability considerations
bioavailability (the fraction of an administered dose that reaches systemic circulation in active form) varies dramatically by route for peptides. oral bioavailability for most peptides is less than 2% because of enzymatic degradation and poor membrane permeability in the gut. subcutaneous injection (injecting under the skin) typically achieves 60-80% bioavailability but requires needles. intranasal bioavailability for small peptides generally falls in the 5-20% range for systemic absorption, but this number underestimates brain delivery because it does not account for the direct nose-to-brain pathway. selank's specific intranasal bioavailability has not been published in Western journals -- most pharmacokinetic data comes from Russian regulatory filings. the practical implication is that intranasal doses need to be higher than injected doses to achieve equivalent blood levels, but may achieve comparable brain levels due to the direct transport route.
where this has been studied
pharmacokinetic and dosing research -- a mix of clinical protocols and preclinical data.
pharmacokinetic studies
pharmacokinetic studies (measuring how the body absorbs, distributes, metabolizes, and excretes a drug over time) in animals show selank reaches peak brain concentrations within minutes of intranasal administration. the peptide is detectable in blood plasma for a shorter period than its biological effects persist, suggesting that brain-level activity outlasts systemic exposure. detailed human PK data has not been published in Western journals.
dose-response data
Russian clinical trials established the 200-300 mcg dose range as the effective window for anxiolytic effects. lower doses (under 100 mcg) produced inconsistent results. higher doses (up to 900 mcg) did not significantly increase efficacy but maintained the clean safety profile, consistent with selank's wide therapeutic index. the dose-response curve appears to plateau rather than continuing to increase linearly.
route comparison studies
preclinical studies comparing intranasal to subcutaneous and intravenous administration show that intranasal delivery achieves disproportionately high brain concentrations relative to blood levels. this supports the nose-to-brain transport hypothesis. subcutaneous injection produces higher and more predictable blood levels but may not achieve the same direct brain delivery advantage.
chronopharmacology
chronopharmacology (studying how the time of day affects drug response) data on selank is limited. Russian clinical protocols specify administration 2-3 times daily, with the first dose in the morning. community users report that timing matters -- morning doses tend to support focus and reduce daytime anxiety, while evening doses occasionally interfere with sleep in sensitive individuals, though selank is not classified as a stimulant.
delivery routes for peptide therapeutics
how intranasal stacks up against other ways to get peptides into the body.
intranasal
- non-invasive -- no needles required
- rapid onset (minutes) via nasal mucosa absorption
- direct nose-to-brain pathway bypasses blood-brain barrier
- bioavailability typically 5-20% for systemic circulation
- used for selank, semax, oxytocin, desmopressin
subcutaneous
- injection under the skin -- requires needles and sterile technique
- high bioavailability (60-80%) with predictable absorption
- must still cross the blood-brain barrier for CNS effects
- slower onset than intranasal (15-30 minutes)
- used for insulin, semaglutide, BPC-157, most peptide drugs
oral
- most convenient -- just swallow a pill or capsule
- very low bioavailability for peptides (under 2%)
- stomach acid and digestive enzymes destroy most peptides
- new formulations (SNAC, enteric coatings) improving results
- oral semaglutide (Rybelsus) is a rare success story
transdermal
- applied to the skin via patches or creams
- very limited for peptides -- skin is a strong barrier
- works only for very small, lipophilic (fat-soluble) molecules
- microneedle patches are an emerging solution
- not used for selank or any currently approved peptide anxiolytic
evidence ceiling: intranasal pharmacokinetic data for selank comes primarily from Russian preclinical and regulatory studies. the nose-to-brain transport pathway is supported by rodent radiolabeling experiments but has not been directly confirmed in humans for selank specifically. community dosing protocols are based on the Russian clinical standard and individual experimentation, not Western clinical trials.
dosing snapshot
the schema, not the protocol. the paid unit unpacks ranges, contraindications, titration, and the semax stack -- this is the floor so nobody has to guess before deciding.
clinical protocol
- 200-300 mcg intranasal
- 3x daily
- 14-day cycle
community variation
- varies widely by source and goal
- specific ranges, contraindications, and titration are in the paid content